Clik here to view.
Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy...
SAN DIEGO Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, today announced that two posters showing...
View ArticleClik here to view.
レビタスバイオがシリーズC資金調達を完了
米カリフォルニア州メンロパーク （ビジネスワイヤ） — ライフサイエンス市場にエンドツーエンドの試料処理・分析サービスを提供する一流企業のレビタスバイオ（www.levitasbio.com）は、業界をリードする強力な細胞分析法を提供するという使命を推進するため、シリーズCラウンドで3500万ドルの資金調達を完了したと発表しました。...
View ArticleClik here to view.
LevitasBio完成C轮融资
加州门洛帕克 (美国商业资讯)–为生命科学市场提供端到端样本处理和分析服务的领先公司LevitasBio, Inc. (www.levitasbio.com)宣布，其已完成C轮3500万美元的融资，用以推进其提供强大的行业领先细胞分析技术的使命。...
View ArticleClik here to view.
エクセンシアが2022年第3四半期の財務業績を2022年11月15日に発表
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq：EXAI）は、2022年9月30日に終了した第3四半期の財務業績を2022年11月15日（火）の米国市場の開場前に発表します。午後1時30分（GMT）／午前8時30分（米東部時間）から、当社は電話会議とウェブキャストを実施し、事業の最新情報と財務業績について説明します。...
View ArticleClik here to view.
Exscientia将于2022年11月15日公布2022年第三季度业绩
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)将于2022年11月15日（周二）美国市场开盘前公布截至2022年9月30日的第三季度财务业绩。公司将于格林尼治标准时间下午1:30/美国东部标准时间上午8:30举行电话会议和网络直播，介绍最新业务情况并回顾财务业绩。...
View ArticleClik here to view.
Guided Therapeutics Provides Update of Significant Progress in Chinese...
PEACHTREE CORNERS, Ga. Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that the clinical trial...
View ArticleClik here to view.
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare...
CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology, today announced BRUKINSA (zanubrutinib) has been approved in...
View ArticleClik here to view.
TAE Life Sciences Announces Partnership with HDX Corporation for Launch of...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with...
View ArticleClik here to view.
Lemonex, IVI Exchange MOU on Joint Vaccine Development
SEOUL, South Korea The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy...
View ArticleClik here to view.
BeiGene Launches Talk About It Program to Elevate the Importance of...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the launch of a new program, Talk About It:...
View ArticleClik here to view.
Exscientia和MD安德森启动战略合作，利用人工智能开发新型肿瘤疗法
英格兰牛津和得克萨斯州休斯敦 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)和得克萨斯大学MD安德森癌症中心今天宣布达成了一项战略合作，将Exscientia以患者为中心的人工智能(AI)能力与MD安德森的药物发现和开发专长相结合，以推进新型小分子肿瘤疗法。...
View ArticleClik here to view.
CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
PHCグループ 中期経営計画 「Value Creation Plan」を改定－「バリューベース・ヘルスケア」の実現に貢献し成長を加速
東京 （ビジネスワイヤ） — PHCホールディングス株式会社（本社: 東京都港区、代表取締役社長CEO：宮﨑 正次、以下「PHCグループ」) は、このたび、PHCグループの中期経営計画「Value Creation Plan」(*1)を改定しましたので、お知らせいたします。PHCグループは、以下に示す３つの成長領域においてバリューベース・ヘルスケアへ貢献することで、更なる成長を目指します。...
View ArticleClik here to view.
PHC Group Releases Newly Revised Mid-Term Plan, the “Value Creation Plan,”...
TOKYO PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: Shoji Miyazaki, hereafter PHC Group) announces the release of its newly revised Mid-term Plan, the “Value...
View ArticleClik here to view.
Genome Insight and Kun-hee Lee Child Cancer ＆ Rare Disease Project Team of...
SAN DIEGO Genome Insight, a precision medicine whole genome platform company, and Kun-hee Lee Child Cancer & Rare Disease Project Team of SNUH (Seoul National University Hospital), funded by the...
View ArticleClik here to view.
HIROTSU BIO SCIENCE INC.: World’s First Test for Early-Stage Pancreatic...
TOKYO HIROTSU BIO SCIENCE INC. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu; hereafter referred to as “HIROTSU”) is pleased to announce the commercialization of “N-NOSE plus...
View ArticleClik here to view.
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib)...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has...
View ArticleClik here to view.
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed...
OSAKA, Japan & CAMBRIDGE, Mass Takeda (TSE:4502/NYSE:TAK) today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with...
View ArticleClik here to view.
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of...
HOUSTON ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has...
View ArticleClik here to view.
Monrol and FutureChem Announced a Clinical Supply Partnership
ISTANBUL & SEOUL Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a...
View Article